Pioglitazone for Heroin and for Nicotine Dependence
Status:
Terminated
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The goal of the proposed research is to improve the effectiveness of treatments for opioid
and for nicotine dependence by testing a novel pharmacological strategy. Specifically,
pioglitazone, a peroxisome proliferator-activated gamma receptor (PPARĪ³) agonist, will be
used as an adjunct to agonist-based treatment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
New York State Psychiatric Institute
Collaborators:
National Institute on Drug Abuse (NIDA) Omeros Corporation